Geron Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$236.3Mnext fiscal year
FY EPS (est.)
-$0.02next fiscal year
Monitoring Framework
Key Performance Indicators
RYTELO (imetelstat) Net Product Revenue Quarterly51.8MTarget: $220 million to $240 million
Total Operating Expenses Quarterly51.7MTarget: $230 million to $240 million
Cash, Cash Equivalents, and Marketable Securities Quarterly341MTarget: Sufficient to fund projected operating requirements for the foreseeable future
Watch Items
- Phase 3 IMpactMF Clinical Trial Interim AnalysisTrigger: Interim overall survival analysis readoutAction: Evaluate overall survival data versus best available therapy to determine potential for second major indication approval in relapsed/refractory myelofibrosis.
- European Commercial Launch and Reimbursement of RYTELOTrigger: Update on European commercial plans and reimbursement statusAction: Assess progress of select EU country launches and pricing integrity preservation relative to U.S. commercial strategy.
Research as of 19 Jun 2026